Skip to main content
ACoP 2024 Main banner
Final Program


Conference Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Brian A. Willis, PhD (he/him/his)

Head of Pharmacometrics
Biogen, Indiana, United States

Brian A. Willis, PhD, is Head of Pharmacometics at Biogen. He graduated from the University of Minnesota College of Pharmacy in 2007, with a PhD in Pharmaceutics. He joined Eli Lilly and Company in the same year as part of the Global PK/PD department. At Lilly, Dr. Willis focused on Lilly's neuroscience portfolio, working in alcohol use disorder and Parkinson's disease, but his major therapeutic area was Alzheimer's disease. He was appointed head of the Pharmacometrics group in 2018, and led the QSP group starting in 2020. He joined Eisai as Head of Pharmacometrics for the Neurology Business Group in 2022, leading modeling and simulation efforts for LEQEMBI. He started at Biogen in August, 2024.

Disclosure(s): Biogen: Employment (Ongoing); Eisai Inc: Employment (Terminated); Eli Lilly: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Presentation(s):